Heat Biologics Inc (NASDAQ:HTBX) is among the notable gainers in the pre-open session on Wednesday.
As of 8:36, HTBX is gaining by 4.37% at $6.68. So far more than 5K shares have exchanged hands.
HTBX Releases News This Morning
Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit
- HTBX today announced that PTX-35 will be featured in several presentations and panel discussions at the 3rd Annual Treg Directed Therapies Summit on May 19-20. PTX-35 is a novel, potential first-in-class antibody modulating TNFRSF25 (death receptor 3 or DR3), a receptor that is preferentially expressed by antigen-experienced T-cells.
- On Wednesday, May 19th at 4PM EDT, Heat Biologics will present: “A Novel TNFRSF25-Agonist for Regulatory T-Cell Expansion.” The presenter, Matthew Seavey, Ph.D., Heat Biologics’ Executive Director of Special Projects, plans to discuss how TNFRSF25-engagement by PTX-35 can expand regulatory T-cells in vivo and reduce disease severity in several animal models of GVHD & inflammatory disease.
- On Thursday, May 20th at 3:30PM EDT, Robert B. Levy, Ph.D., Professor of Microbiology and Immunology at the University of Miami Miller School of Medicine, will present: “Improving Outcomes of Allo-HCT: Manipulating the Regulatory Cell Compartment in vivo to Ameliorate GVHD.”
|SHARES OUTSTANDING||25.25 M|
|SHARE FLOAT (%)||24.13 M (95.53%)|
|% HELD BY INSTITUTIONS||10.65|
Recent Stock Performance
|+/- EMA(20)||6.49 (-1.39%)|
|+/- SMA(50)||7.21 (-11.23%)|
|+/- SMA(200)||8.06 (-20.60%)|
|CCI20||-36.6171||Neutral||Chaikin Money Flow||-0.0151||Neutral|
|MACD||-0.3506||Sell||Money Flow Index||23.7572||Sell|
|STOCH (14,3)||41.8605||Buy||STOCH RSI||1.0000||OverBought|